Caricamento...
Overcoming immunosuppression to enhance a p53MVA vaccine
A Phase I trial of a p53-targeting modified vaccinia Ankara (p53MVA) vaccine in patients afflicted with refractory gastrointestinal cancers demonstrated enhanced T-cell recognition of p53 following vaccination. However, this effect was transient suggesting that p53MVA requires combination with immun...
Salvato in:
| Pubblicato in: | Oncoimmunology |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Taylor & Francis
2014
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4292557/ https://ncbi.nlm.nih.gov/pubmed/25941580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/21624011.2014.958949 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|